India’s First COVID-19 Under-Trial Vaccine ‘COVAXIN’ Approved For Human Trials

India’s first Corona Virus vaccine candidate ‘COVAXIN’ developed by Hyderabad-based Bharat Biotech recieved an approval from the Drug Controller General of India (DCGI) to conduct human clinical trials. The vaccine is developed in collaboration with ICMR, The University of WISCONSIN, and Thomas Jefferson University. Who developed COVAXIN? 

The indigenous and inactivated vaccine has been developed at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) high containment facility located in the Genome Valley, Hyderabad.

When will the human clinical trials for COVAXIN begin?

COVAXIN phase I and II human clinical trials will commence from July 2020 across the entire country.

When will COVAXIN be available in the market?

At present, no confirmed information is available as to when the vaccine will be available for use in the market.

 

For more such alerts and updates, stay updated on our website and follow @dutimes on Instagram.

Coronavirus
Covid-19
India WorldWorld
+0 (24h)
0
Confirmed
0
+0 (24h)
0
Deaths
0
NAN%
0
Recovered
0
NAN%
0
Active
+0 (24h)
0
Confirmed
0
+0 (24h)
0
Deaths
0
NAN%
0
Recovered
0
NAN%
0
Active

LEAVE A REPLY

Please enter your comment!
Please enter your name here